Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (10859)	2/21/2012 11:04:10 AM
From: jm2i123	Read Replies (2) \| Respond to of 13111

why would a market reduce when both drugs are not yet on sale, pv-10 has not been approved yet and may have better data, and no one knows what the consumer/prescription "maker" will do? I am not going to claim that big companies being approved is good news for pvct when we're still waiting for the Spa but once approved it could actually raise the profile of PVCT a tod higher... Competing with those giants, in my little book, means we have a benchmark > higher price tag (for the drug and for the company) EVEN if the trial results are slightly behind Roche. We've seen that many times.